Evidence map›Paper›PMID 30267249›Full record

ReviewBreast cancer research and treatment2019

Male breast cancer: a disease distinct from female breast cancer.

Ayca Gucalp, Tiffany A Traina, Joel R Eisner, Joel S Parker, Sara R Selitsky, Ben H Park, Anthony D Elias, Edwina S Baskin-Bey, Fatima Cardoso

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Breast cancer research and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 204 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
204citing papers in PubMed, 7 pooled it
20.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

204 citing papers in PubMed, 7 syntheses or guidelines pooled it, 372 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. An interpretable breast cancer risk stratification model via multi-omics integration: multi-method development and cross-cohort validation.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. The Oncotype DX® 21-gene recurrence score and clinical outcomes in hormone receptor-positive, HER2-negative male breast cancer: a scoping review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  20. Article

144 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Ayca GucalpDepartment of Medicine, Memorial Sloan Kettering Cancer Center, Evelyn H. Lauder Breast Center, 300 East 66th Street, New York, NY, USA. gucalpa@mskcc.org.ORCID http://orcid.org/0000-0002-3600-3751
Tiffany A TrainaDepartment of Medicine, Memorial Sloan Kettering Cancer Center, Evelyn H. Lauder Breast Center, 300 East 66th Street, New York, NY, USA.
Joel R EisnerInnocrin Pharmaceuticals Inc., Durham, NC, USA.
Joel S ParkerDepartment of Genetics, University of North Carolina, Chapel Hill, NC, USA.
Sara R SelitskyLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Ben H ParkJohns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Anthony D EliasDepartment of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Edwina S Baskin-BeyInnocrin Pharmaceuticals Inc., Durham, NC, USA.
Fatima CardosoBreast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.
Innocrin Pharmaceuticals (United States) · USMemorial Sloan Kettering Cancer Center · USUniversity of North Carolina at Chapel Hill · USChampalimaud Foundation · PTSidney Kimmel Comprehensive Cancer Center · USUniversity of Colorado Anschutz Medical Campus · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeMale breast cancer (BC) is rare, representing approximately 1% of cancers that occur in men and approximately 1% of all BCs worldwide. Because male BC is rare, not much is known about the disease, and treatment recommendations are typically extrapolated from data available from clinical trials enrolling female BC patients.

methodsWe review the epidemiology, risk factors, prognosis, and the varied molecular and clinicopathologic features that characterize male BC. In addition, we summarize the available data for the use of systemic therapy in the treatment of male BC and explore the ongoing development of targeted therapeutic agents for the treatment of this subgroup of BCs.

resultsThere are important biological differences between male and female BC. Male BC is almost exclusively hormone receptor positive (+), including the androgen receptor (AR), and is associated with an increased prevalence of BRCA2 germline mutations, especially in men with increased risk for developing high-risk BC. Additional research is warranted to better characterize male BC. To accomplish this, a multi-national consortium approach, such as the International Male Breast Cancer Program, is needed in response to the scarcity of patients. This approach allows the pooling of information from a large number of men with BC and the creation of registries for future therapeutic-focused clinical trials.

conclusionsGiven the unique biology of BC in men, promising new therapeutic targets are currently under investigation, including the use of poly-ADP-ribose polymerase inhibitors or AR-targeted agents either as monotherapy or in combination with other agents.

Indexed as

Antineoplastic AgentsBreast NeoplasmsBreast Neoplasms, MaleClinical Trials as TopicEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticHumansMaleSEER ProgramAntineoplastic AgentsAndrogen and estrogen biosynthesis inhibitionAndrogen receptorAnti-androgenBiomarkersEndocrine therapyMale breast cancer

Identifiers

PMID30267249
PMCPMC7513797
OpenAlexW2893465708

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.